Ahmed, G., Abed, M., Alassaf, F. (2023). An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients. Alustath, 20(1), 65-71. doi: 10.33899/iphr.2023.137946.1041
Ghada M Ahmed; Mohammed N Abed; Fawaz A Alassaf. "An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients". Alustath, 20, 1, 2023, 65-71. doi: 10.33899/iphr.2023.137946.1041
Ahmed, G., Abed, M., Alassaf, F. (2023). 'An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients', Alustath, 20(1), pp. 65-71. doi: 10.33899/iphr.2023.137946.1041
Ahmed, G., Abed, M., Alassaf, F. An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients. Alustath, 2023; 20(1): 65-71. doi: 10.33899/iphr.2023.137946.1041

An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients

Iraqi Journal of Pharmacy
Article 10, Volume 20, Issue 1, June 2023, Pages 65-71    PDF (743.9 K)
Document Type: Review Paper
DOI: 10.33899/iphr.2023.137946.1041
Authors
Ghada M Ahmed1; Mohammed N Abed* 2; Fawaz A Alassaf3, 4
1Nineveh health directorate, Mosul, Nineveh province, Iraq
2Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq
3Pharmacology and Toxicology Department, College of Pharmacy, University of Mosul, Mosul, Iraq
4College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq
Abstract
Background: Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2-IS) have been shown to increase hemoglobin (Hb) levels, hematocrit, and erythrocyte count. It has also been found that these agents can potentially reduce the risk of anemia and minimize the need for erythropoiesis stimulating agents (ESA) and other treatments in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). However the precise mechanism for such an effect is still conflicting. Aim: We aimed at providing an overview of the effects of SGLT2-IS on hematological parameters, specifically focusing on their potential to improve anemia and erythropoiesis in patients with diabetes mellitus (DM). Additionally the proposed mechanisms by which SGLT2-IS may improve Hb levels besides their clinical importance and future directions will also be highlighted. Results: Based on the obtained data from latest literatures, SGLT2-IS may improve the status of anemia and other linked abnormalities via their mild diuretic potential, effects on erythropoietin (EPO) production, and possible increase in renal oxygen delivery. Conclusion: SGLT2-IS may have a promising role in improving multiple aspects of blood, circulatory and renal systems health in patients with DM, beyond their primary glucose-lowering role.
Keywords
SGLT2 inhibitors; Anemia; Erythropoietin
References
  1. Xie L, Shao X, Yu Y, Gong W, Sun F, Wang M, et al. Anemia is a risk factor for rapid eGFR decline in type 2 diabetes. Frontiers in Endocrinology 2023;14:1–9.
  2. AlDallal SM, Jena N. Prevalence of Anemia in Type 2 Diabetic Patients. Journal of Hematology 2018;7(2):57–61.
  3. Albai O, Timar B, Paun DL, Sima A, Roman D, Timar R. Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020;Volume 13:3873–8.
  4. N. Abed M. Effect of atorvastatin in combination with different oral antidiabetic medications on lipid parameters and glucose level. Iraqi Journal of Pharmacy 2013;13(2):62–9.
  5. Vieira, Souto, Sánchez-López, Machado, Severino, Jose, et al. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I. Pharmaceuticals 2019;12(4):152.
  6. Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annual Review of Physiology 2021;83(1):503–28.
  7. Szekeres Z, Toth K, Szabados E. The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites 2021;11(2):87.
  8. Lin HW, Tseng CH. A Review on the Relationship between SGLT2 Inhibitors and Cancer. International Journal of Endocrinology 2014;2014:1–6.
  9. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Medicine 2010;27(2):136–42.
  10. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. American Journal of Physiology-Renal Physiology 2015;309(11):F889–900.
  11. Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. International Journal of Environmental Research and Public Health 2019;16(16):2965.
  12. Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, et al. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus. Cureus 2021;13(8):e16868.
  13. Raza S, Osasan S, Sethia S, Batool T, Bambhroliya Z, Sandrugu J, et al. A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection. Cureus 2022;2(6):1–11.
  14. Malhotra A, Kudyar S, Gupta AK, Kudyar RP, Malhotra P. Sodium glucose co-transporter inhibitors - A new class of old drugs. International journal of applied & basic medical research 2015;5(3):161–3.
  15. Londzin P, Siudak S, Cegieła U, Pytlik M, Janas A, Waligóra A, et al. Phloridzin, an Apple Polyphenol, Exerted Unfavorable Effects on Bone and Muscle in an Experimental Model of Type 2 Diabetes in Rats. Nutrients 2018;10(11):1701.
  16. Nauck M. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy 2014;1335.
  17. Malhotra A, Kudyar S, Gupta A, Kudyar R, Malhotra P. Sodium glucose co-transporter inhibitors – A new class of old drugs. International Journal of Applied and Basic Medical Research 2015;5(3):161.
  18. Ortiz-Martínez M, González-González M, Martagón AJ, Hlavinka V, Willson RC, Rito-Palomares M. Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Current Diabetes Reports 2022;22(3):95–115.
  19. Ketema EB, Kibret KT. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Archives of Public Health 2015;73(1):43.
  20. Brust-Sisti L, Rudawsky N, Gonzalez J, Brunetti L. The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. Pharmacy 2022;10(6):166.
  21. Abdul-Ghani MA, DeFronzo RA. Dapagliflozin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 2013;14(12):1695–703.
  22. Singh H, Thangaraju P, Singh J, Kaushal S. Canagliflozin: A novel SGLT2 inhibitor for type 2 diabetes mellitus. North American Journal of Medical Sciences 2014;6(3):107.
  23. Choi CI. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents. Molecules 2016;21(9):1136.
  24. Wang A, Li Z, Zhuo S, Gao F, Zhang H, Zhang Z, et al. Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. Frontiers in cardiovascular medicine 2022;9:857952.
  25. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports 2022;7(7):1463–76.
  26. Baruah M, Makkar B, Ghatnatti V, Mandal K. Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control. Indian Journal of Endocrinology and Metabolism 2019;23(1):140.
  27. Bajaj S, Makkar BM, Abichandani VK, Talwalkar PG, Saboo B, Srikanta SS, et al. Management of anemia in patients with diabetic kidney disease: A consensus statement. Indian journal of endocrinology and metabolism 2016;20(2):268–81.
  28. Rizzo C, Carbonara R, Ruggieri R, Passantino A, Scrutinio D. Iron Deficiency: A New Target for Patients With Heart Failure. Frontiers in Cardiovascular Medicine 2021;8(August):709872.
  29. Sandhu A, Soman S, Hudson M, Besarab A. Managing anemia in patients with chronic heart failure: what do we know? Vascular health and risk management 2010;6:237–52.
  30. Manns BJ, Tonelli M. The New FDA Labeling for ESA—Implications for Patients and Providers. Clinical Journal of the American Society of Nephrology 2012;7(2):348–53.
  31. Provatopoulou ST, Ziroyiannis PN. Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects. Hippokratia 2011;15(2):109–15.
  32. Drüeke TB. Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs). Renal Replacement Therapy 2018;4(1):46.
  33. Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences 2022;23(7):3651.
  34. Aberle J, Menzen M, Schmid SM, Terkamp C, Jaeckel E, Rohwedder K, et al. Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes. Scientific Reports 2020;10(1):22396.
  35. Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, et al. Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease. Diabetes technology & therapeutics 2019;21(12):713–20.
  36. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. Journal of clinical medicine research 2016;8(12):844–7.
  37. Onyali CB, Anim-Koranteng C, Shah HE, Bhawnani N, Ethirajulu A, Alkasabera A, et al. Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control. Cureus 2021;13(8):e17452.
  38. Oshima M, Neuen BL, Jardine MJ, Bakris G, Edwards R, Levin A, et al. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. The Lancet Diabetes & Endocrinology 2020;8(11):903–14.
  39. Stefánsson B V., Heerspink HJL, Wheeler DC, Sjöström CD, Greasley PJ, Sartipy P, et al. Correction of anemia by dapagliflozin in patients with type 2 diabetes. Journal of Diabetes and its Complications 2020;34(12):107729.
  40. Murashima M, Tanaka T, Kasugai T, Tomonari T, Ide A, Ono M, et al. Sodium–glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice. Journal of Diabetes Investigation 2022;13(4):638–46.
  41. Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Current opinion in nephrology and hypertension 2020;29(2):190–8.
  42. Burnier M. Sodium-glucose cotransporter 2 (SGLT-2) inhibition and kidney protection: Does improvement in kidney hypoxia play a role? eClinicalMedicine 2021;37:100983.
  43. Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, et al. Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease. Diabetes Technology & Therapeutics 2019;21(12):713–20.
  44. Isidto R, Danguilan R, Naidas O, Vilanueva R, Arakama MH, Paraiso LM. Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease. International Journal of Nephrology and Renovascular Disease 2023;16(2023):43–57.
  45. Fukushima K, Kitamura S, Tsuji K, Wada J. Sodium-Glucose Cotransporter 2 Inhibitors Work as a “Regulator” of Autophagic Activity in Overnutrition Diseases. Frontiers in pharmacology 2021;12:761842.
  46. Packer M. Interplay of adenosine monophosphate‐activated protein kinase/sirtuin‐1 activation and sodium influx inhibition mediates the renal benefits of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: A novel conceptual framework. Diabetes, Obesity and Metabolism 2020;22(5):734–42.
  47. Qu W, Yao L, Liu X, Xu T, Tian B. Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials. Frontiers in Pharmacology 2021;12(March):630820.
  48. Gao YM, Feng ST, Wen Y, Tang TT, Wang B, Liu BC. Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming. eBioMedicine 2022;83:104215.
  49. Sano M. A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome. International Journal of Molecular Sciences 2023;24(6):5983.
  50. Osorio H, Coronel I, Arellano A, Pacheco U, Bautista R, Franco M, et al. Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats. Oxidative Medicine and Cellular Longevity 2012;2012:1–7.
  51. Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. Cardiovascular Diabetology 2022;21(1):45.
  52. Iannantuoni F, M. de Marañon A, Diaz-Morales N, Falcon R, Bañuls C, Abad-Jimenez Z, et al. The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. Journal of Clinical Medicine 2019;8(11):1814.
  53. Pignatelli P, Baratta F, Buzzetti R, D’Amico A, Castellani V, Bartimoccia S, et al. The Sodium–Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. Antioxidants 2022;11(10):1878.
  54. Lescano CH, Leonardi G, Torres PHP, Amaral TN, de Freitas Filho LH, Antunes E, et al. The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation. Biochemical Pharmacology 2020;182:114276.
  55. Kowalska K, Wilczopolski P, Buławska D, Młynarska E, Rysz J, Franczyk B. The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. Antioxidants 2022;11(12):2500.
  56. Kyriakos G, Quiles-Sanchez L V., Garmpi A, Farmaki P, Kyre K, Savvanis S, et al. SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study. Current Cardiology Reviews 2021;16(4):258–65.
  57. Barbieri J, Fontela PC, Winkelmann ER, Zimmermann CEP, Sandri YP, Mallet EKV, et al. Anemia in Patients with Type 2 Diabetes Mellitus. Anemia 2015;2015(2):1–7.
  58. Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 2018;61(10):2098–107.
  59. Li M, Yi T, Fan F, Qiu L, Wang Z, Weng H, et al. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis. Cardiovascular Diabetology 2022;21(1):139.
  60. Kario K, Ferdinand KC, Vongpatanasin W. Are SGLT2 Inhibitors New Hypertension Drugs? Circulation 2021;143(18):1750–3.
  61. Liu Z, Ma X, Ilyas I, Zheng X, Luo S, Little PJ, et al. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics 2021;11(9):4502–15.
  62. La Grotta R, de Candia P, Olivieri F, Matacchione G, Giuliani A, Rippo MR, et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cellular and Molecular Life Sciences 2022;79(5):273.
  63. Yaribeygi H, Atkin SL, Jamialahmadi T, Sahebkar A. A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function. Endocrine, Metabolic & Immune Disorders - Drug Targets 2020;20(3):328–34.
  64. Tanaka A, Imai T, Shimabukuro M, Nakamura I, Matsunaga K, Ozaki Y, et al. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial. Journal of Diabetes Investigation 2022;13(12):1990–9.
  65. Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs 2019;79(3):219–30.
  66. Cho YK, Kim YJ, Jung CH. Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis. Journal of Obesity & Metabolic Syndrome 2021;30(4):336–44.
  67. Bailey CJ, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Current Diabetes Reports 2022;22(1):39–52.
  68. Tsai SF, Tarng DC. Anemia in patients of diabetic kidney disease. Journal of the Chinese Medical Association 2019;82(10):752–5.
  69. Heerspink HJL, Stefánsson B V., Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine 2020;383(15):1436–46.
  70. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine 2019;380(24):2295–306.
  71. Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Advances in Therapy 2022;39(1):148–64.
  72. Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Advances in therapy 2022;39(1):148–64.
  73. Gohda T, Murakoshi M. Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials. International Journal of Molecular Sciences 2022;23(22):13749.
  74. Unnikrishnan AG, Kalra S, Purandare V, Vasnawala H. Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus. Indian journal of endocrinology and metabolism 2018;22(6):837–42.
  75. Yang H, Choi E, Park E, Na E, Chung SY, Kim B, et al. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea. Pharmacology research & perspectives 2022;10(1):e00910.
  76. Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S. The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study. Medicines 2022;9(12):59.
  77. Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018;363:k4365.
  78. Lee MK, Kim B, Han K, Lee JH, Kim M, Kim MK, et al. Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study. Diabetes Care 2021;44(10):2419–26.
  79. Yang H, Choi E, Park E, Na E, Chung SY, Kim B, et al. Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea. Pharmacology Research & Perspectives 2022;10(1):e00910.
  80. Hropot T, Battelino T, Dovc K. Sodium-glucose co-transporter-2 inhibitors in Type 1 Diabetes: A Scoping Review. Hormone Research in Paediatrics 2022;
  81. Bashier A, Khalifa AA, Rashid F, Abdelgadir EI, Al Qaysi AA, Ali R, et al. Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes. Journal of clinical medicine research 2017;9(6):499–507.
  82. Wang L, Voss EA, Weaver J, Hester L, Yuan Z, DeFalco F, et al. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiology and Drug Safety 2019;28(12):1620–8.
  83. Fattah H, Vallon V. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. Drugs 2018;78(7):717–26.
  84. Pasqua MR, Tsoukas MA, Haidar A. Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy. Journal of Diabetes Science and Technology 2021;15(6):1232–42.
  85. Adler AI, Cronshaw J, Prescott C, Patel S, Donegan E, Hayre J. NICE guidance on sotagliflozin for type 1 diabetes. The Lancet Diabetes & Endocrinology 2020;8(4):274–5.
  86. He X, Gao X, Xie P, Liu Y, Bai W, Liu Y, et al. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects. Drug Design, Development and Therapy 2022;Volume 16:2967–80.
Statistics
Article View: 119
PDF Download: 50


Journal Management System. Powered by ejournalplus